ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Recurrence
Mantle-Cell Lymphoma

Non-Hodgkin Lymphoma trials near Portland, OR, USA:

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Portland, Oregon, United States and 41 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Portland, Oregon, United States and 37 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Portland, Oregon, United States and 48 other locations

in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized ster...

Enrolling
B-Cell Non-Hodgkins Lymphoma
Drug: Glofitamab
Drug: Gemcitabine

Phase 2

Roche
Roche

Portland, Oregon, United States and 52 other locations

This study has 2 parts.The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non...

Active, not recruiting
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Drug: Chemotherapy Agents
Biological: TAK-007

Phase 2

Takeda
Takeda

Portland, Oregon, United States and 14 other locations

Locations recently updated

monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...

Enrolling
Large B-Cell Lymphoma (LBCL)
B-cell Non-Hodgkin Lymphoma
Drug: Surovatamig

Phase 2

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 92 other locations

and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refr...

Active, not recruiting
B-cell Non-Hodgkin Lymphoma (B-NHL)
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Biological: PIT565

Phase 1

Novartis
Novartis

Portland, Oregon, United States and 17 other locations

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Drug: Isatuximab
Drug: Mesna

Phase 1, Phase 2

Indapta Therapeutics

Portland, Oregon, United States and 11 other locations

safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts A-C)
Drug: Mosunetuzumab (Cohorts D-E)

Phase 2

Genentech
Genentech

Portland, Oregon, United States and 40 other locations

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with o...

Enrolling
B-cell Non-Hodgkin Lymphoma
Small Lymphocytic Lymphoma
Drug: Rituximab
Drug: Vincristine

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 62 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems